Abbott ADHD Drug Cylert Withdrawn But FDA Stops Short Of Immediate Recall
Executive Summary
FDA is opting for a phased withdrawal of pemoline products (Abbott's Cylert and generics) rather than a full recall to give patients time to transition to alternate therapies
You may also be interested in...
FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question
Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C
FDA Stays Positive On Rx Safety Info Sheets, But Drug Watch Still In Question
Drug information sheets published by FDA in 2005 demonstrate the agency's focus on important safety issues, Drug Safety Oversight Board Executive Director Susan Cummins said Jan. 23 at a Drug Information Association conference in Washington, D.C
ADHD Suicidal Thinking Health Advisory Limited To Lilly’s Strattera
FDA does not intend to release a general public health advisory for attention deficit/hyperactivity disorder medications despite issuing one for Lilly's Strattera (atomoxetine) Sept. 29